Journal
AMERICAN JOURNAL OF TRANSPLANTATION
Volume 23, Issue 2, Pages 278-283Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.ajt.2022.10.004
Keywords
clinical research/practice; infectious disease; complication: infectious, infection, and infectious agents - viral: SARS-COV-2/COVID-19
Categories
Ask authors/readers for more resources
Mutations in the spike protein of SARS-CoV-2 allow Omicron subvariants to evade neutralizing antibodies, and this phenomenon in transplant recipients is not well understood. This study examined crossneutralizing responses in transplant recipients who previously recovered from BA.1 infection. The results showed that neutralizing antibody responses against BA.4/5 were significantly lower than those against BA.1, and these responses declined over time.
Mutations in the spike protein of SARS-CoV-2 have allowed Omicron subvariants to escape neutralizing antibodies. The degree to which this occurs in transplant recipients is poorly understood. We measured BA.4/5 crossneutralizing responses in 75 mostly vaccinated transplant recipients who recovered from BA.1 infection. Sera were collected at 1 and 6 months post-BA.1 infection, and a lentivirus pseudovirus neutralization assay was performed using spike constructs corresponding to BA.1 and BA.4/5. Uninfected immunized transplant recipients and health care worker controls were used for comparison. Following BA.1 infection, the proportion of transplant recipients with neutralizing antibody responses was 88.0% (66/75) against BA.1 and 69.3% (52/75) against BA.4/5 (P = .005). The neutralization level against BA.4/5 was approximately 17-fold lower than that against BA.1 (IQR 10.6- to 45.1-fold lower, P < .0001). BA.4/5 responses declined over time and by =0.5 log10 (approximately 3-fold) in almost half of the patients by 6 months. BA.4/5-neutralizing antibody titers in transplant recipients with breakthrough BA.1 infection were similar to those in immunized health care workers but significantly lower than those in uninfected triple-vaccinated transplant recipients. These results provide evidence that transplant recipients are at ongoing risk for BA.4/5 infection despite vaccination and prior Omicron strain infection, and additional mitigation strategies may be required to prevent severe disease in this cohort.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available